TY - JOUR
T1 - Assessment of established techniques to determine developmental and malignant potential of human pluripotent stem cells
AU - Allison, Thomas F.
AU - Andrews, Peter W.
AU - Avior, Yishai
AU - Barbaric, Ivana
AU - Benvenisty, Nissim
AU - Bock, Christoph
AU - Brehm, Jennifer
AU - Brüstle, Oliver
AU - Damjanov, Ivan
AU - Elefanty, Andrew
AU - Felkner, Daniel
AU - Gokhale, Paul J.
AU - Halbritter, Florian
AU - Healy, Lyn E.
AU - Hu, Tim X.
AU - Knowles, Barbara B.
AU - Loring, Jeanne F.
AU - Ludwig, Tenneille E.
AU - Mayberry, Robyn
AU - Micallef, Suzanne
AU - Mohamed, Jameelah S.
AU - Müller, Franz Josef
AU - Mummery, Christine L.
AU - Nakatsuji, Norio
AU - Ng, Elizabeth S.
AU - Oh, Steve K.W.
AU - O'Shea, Orla
AU - Pera, Martin F.
AU - Reubinoff, Benjamin
AU - Robson, Paul
AU - Rossant, Janet
AU - Schuldt, Bernhard M.
AU - Solter, Davor
AU - Sourris, Koula
AU - Stacey, Glyn
AU - Stanley, Edouard G.
AU - Suemori, Hirofumi
AU - Takahashi, Kazutoshi
AU - Yamanaka, Shinya
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC's malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment of pluripotency and malignant potential, which are both relevant to the pre-clinical safety assessment of PSCs.
AB - The International Stem Cell Initiative compared several commonly used approaches to assess human pluripotent stem cells (PSC). PluriTest predicts pluripotency through bioinformatic analysis of the transcriptomes of undifferentiated cells, whereas, embryoid body (EB) formation in vitro and teratoma formation in vivo provide direct tests of differentiation. Here we report that EB assays, analyzed after differentiation under neutral conditions and under conditions promoting differentiation to ectoderm, mesoderm, or endoderm lineages, are sufficient to assess the differentiation potential of PSCs. However, teratoma analysis by histologic examination and by TeratoScore, which estimates differential gene expression in each tumor, not only measures differentiation but also allows insight into a PSC's malignant potential. Each of the assays can be used to predict pluripotent differentiation potential but, at this stage of assay development, only the teratoma assay provides an assessment of pluripotency and malignant potential, which are both relevant to the pre-clinical safety assessment of PSCs.
UR - http://www.scopus.com/inward/record.url?scp=85047190636&partnerID=8YFLogxK
U2 - 10.1038/s41467-018-04011-3
DO - 10.1038/s41467-018-04011-3
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 29765017
AN - SCOPUS:85047190636
SN - 2041-1723
VL - 9
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1925
ER -